Bayer facing opposition to Canesten move in NZ
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Bayer’s proposed down-scheduling of its Canesten Plus antifungal cream from pharmacist-only to pharmacy-only status in New Zealand is facing opposition from the country’s pharmacists.